Introduction
Dual antiplatelet therapy with the cyclooxygenase inhibitor aspirin and a P2Y 12 receptor antagonist has been pivotal in the era of percutaneous coronary intervention as a mainstay treatment of ischaemic heart disease. 1 Until recently, their primary indication was to reduce the risk of thrombosis. However, it has become increasingly accepted that P2Y 12 antagonists may exert additional benefit via off-target effects. As such, P2Y 12 antagonists have demonstrated, at both experimental 2, 3 and clinical 4,5 levels, to reduce the size of infarction. However, regardless of their antiplatelet efficacy, P2Y 12 antagonists have been shown to differ in their ability to limit infarct size. [6] [7] [8] [9] This is of key importance since infarct size is a major determinant of post-ST-elevation myocardial infarction (STEMI) morbidity and mortality. 10 We have recently demonstrated by cardiac magnetic resonance (CMR) in a preclinical experimental model of myocardial infarction (MI) that both clopidogrel and ticagrelor administration prior-MI acutely reduce infarct size measured at 24 h, and that the effect was significantly greater in ticagrelor-treated animals. 2 Interestingly, the cardioprotective effects of ticagrelor were associated with the attenuation in oedema formation, an effect not reported in clopidogrel-treated pigs. 2 These differences suggest that the degree of cardioprotection may vary between P2Y 12 antagonist classes (clopidogrel/thienopyridine vs. ticagrelor/cyclopentyltriazolopyrimidine) partly explaining the clinical benefit found in ticagrelor-treated patients in the PLATO trial. 11, 12 Although the underlying molecular mechanisms by which platelet P2Y 12 antagonists mediate cardioprotection remain to be elucidated, they have been shown to exhibit an ischaemic conditioning-like effect. 4 Particularly, ticagrelor has been shown to protect the heart against MI mainly through adenosine-related mechanisms. 2, 7 In this regard, by blocking the equilibrative nucleoside transporter 1 (ENT-1) transporter, ticagrelor prevents erythrocyte re-uptake of extracellular adenosine released upon the ischaemic insult consequently leading to elevated and persistent local extracellular adenosine levels. 13 Adenosine, in turn, has shown to trigger and mediate endogenous cardioprotection. 14 Infarct size determines the progression to left ventricular (LV) remodelling and eventual development of heart failure. 15 The LV healing process has been arbitrarily divided into an early phase (within 3 days) and a late phase (beyond 3 days). The early phase involves expansion of the infarct zone whereas the late phase involves the global LV function. 16 The effect of ticagrelor on cardiac response post-MI has previously been assessed in a rat model, where chronic ticagrelor administration resulted in smaller infarcts and improved ventricular function at 4 weeks, effects not reported for clopidogrel. 8 However, no data are yet available on the effects of both P2Y 12 antagonists on global functional and anatomical parameters, as well as on regional parameters of cardiac remodelling (16-segment model) in a large animal model by use of state-of-the art imaging modality. Hence, to understand the full range of effects elicited by the two classes of P2Y 12 antagonists, we have investigated in a pig MI model and by segmented CMR imaging at 3 days (early phase) and at a late phase (42 days) post-MI, whether administration of the drugs in the setting of MI and chronically thereafter reduces infarct size and consequently attenuates LV dysfunction. Furthermore, structural and molecular analyses have been performed.
Methods
The experimental procedures with animals were reviewed and approved by the Institutional Animal Care and Use Committees (CEEA-IR) and authorized by the Animal Experimental Committee of the local government (#5601) in accordance to the Spanish law (RD 53/2013) and European Directive 2010/63/EU. In addition, the investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985) and has followed the ARRIVE guidelines and committed to the 3Rs of laboratory animal research and consequently used the minimal number of animals to reach statistical conclusion. 17 All animals were allowed to acclimate 7 days prior to any intervention and housed in individual cages under light-controlled conditions and room temperature.
Experimental design
Regular chow-fed Landrace pigs (n = 24; weight %43 kg; Specipig SL, Spain) were randomly (Excel randomized function) distributed into three groups to blindly receive: (i) placebo control (n = 8); (ii) a loading dose of clopidogrel (600 mg; n = 8; 4 h prior-MI); and (iii) a loading dose of ticagrelor (180 mg; n = 8; 2 h prior-MI induction).
The study timing and doses were chosen based on our previously published data with the goal to reach comparable degree of platelet inhibition. As such, adenosine diphosphate (ADP) (20 mM)-induced platelet aggregation was inhibited by 68.2% in clopidogrel-treated animals and by 62.2% in ticagrelor-treated pigs [P = non significant (NS)]. 2 In addition,
we performed a sub-study in six pigs in which we assessed the platelet inhibitory effects of both treatment regimes by light transmittance aggregometry induced by ADP (5, 10, and 20 mM) over a follow-up of 8 days.
As shown in Supplementary material online, Figure S1 and in line with our previous work, 2 administration of the selected treatment regimes lead to a comparable degree of platelet inhibition in both groups that persisted over time. These results allow us to exclude any potential effect of the drugs due to different power in platelet inhibition. These dosages, in turn, concur with the dosages used in the PLATO trial.
2,11
Pigs underwent temporary (1 h) balloon occlusion of the mid-left anterior descending coronary artery (experimental MI), 2 and thereafter, were brought back to the animal facility to recover. Throughout the following 42 days, the pigs received the daily maintenance doses of the antiplatelet agents (90 mg/bid for ticagrelor and 75 mg/qd for clopidogrel, respectively).
To ensure the blind administration of the treatment, we directly and daily gave the pills to a technician of the animal facilities in charge of animal maintenance but not involved in conducting the experimental protocol. At Day 3 and Day 42 post-MI, animals were anaesthetized and brought to the 3T-CMR facility for blind assessment of global and regional parameters. Animals were euthanized after the last CMR analysis (Day 42).
Experimental induction of MI
On the day of MI-induction animals received buprenorphine (0.03 mg/ kg) and cefazoline (25 mg/kg) as prophylaxis for pain and wound infection, respectively, and then anaesthetized by administrating an intramuscular injection of ketamine (30 mg/kg), xylazine (2.2 mg/kg), and atropine (0.05 mg/kg). Once tranquilized, animals were endotracheally intubated and anaesthesia was maintained by isoflurane inhalation (2%). Prior to starting the MI-induction procedure, an infusion of amiodarone (300 mg) and lidocaine (150 mg) in 1.000 mL of saline (250 mL/h) was initiated as prophylaxis for malignant ventricular arrhythmias through a line placed in the marginal ear vein and a bolus of heparin (100 U/kg) was administered to prevent clot formation in the catheters. MI was experimentally induced by a minimally invasive closed chest myocardial balloon occlusion of the mid-portion of the left anterior descending coronary artery as previously described. 2 Complete coronary ischaemia (verified by angiography) was maintained for 1 h. At the end of the ischaemic period, the balloon was completely deflated and animals were allowed to recover. Electrocardiographic (ECG) and haemodynamic parameters were continuously recorded throughout the entire procedure and the echocardiographic system (Phillips iE33) equipped with a S5-1 sector array transducer was used prior-and post-MI induction to document the initial worsening of left ventricular ejection fraction (LVEF, M-mode analysis using the parasternal long-axis view).
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3T-CMR acquisition
CMR studies were conducted serially in all animals at Day 3 (early remodelling phase) and Day 42 (late remodelling phase) post-MI. The studies were performed on a 3.0T-CMR system (Achieva V R , Philips, Amsterdam, The Netherlands) and CMR image acquisition was carried out by a CMRspecialized technician blinded in terms of treatment. For CMR studies, animals were anaesthetized with an intramuscular injection of a cocktail composed of ketamine, xylazine, and atropine and maintained by a continuous intravenous infusion of propofol to ensure mechanical ventilation. Once the animals were positioned in a head-first supine position with a flexible phased-array surface coil placed over the chest, ECG gating was used to acquire still images of the heart. The following dedicated CMR sequences were acquired in all cases: 'cine' Balanced Steady-State Free Precession (bSSFP) imaging sequence to assess wall motion (WM) and cardiac function; T2-weighted short-tau inversion recovery (T2w-STIR) sequence to assess myocardial oedema; early gadolinium enhancement to study microvascular obstruction (no-reflow phenomenon); and late gadolinium enhancement (LGE) to assess the amount and extent of myocardial necrosis. All the CMR studies followed the same scheme. First, scout images [T1-turbo field echo (TFE) sequence] were obtained to localize the true axes of the heart and define a field of view involving the whole heart. Afterwards, the bSSFP cine imaging was performed in both horizontal and vertical long axes (four-chamber and two-chamber views) and in multiple contiguous short-axis images covering the whole LV. In the short-axis cine sequence, we acquired 24 cardiac phases of every slice to guarantee a correct evaluation of the WM and heart function. Once the cine sequences were acquired, a T2w-STIR sequence was obtained to assess myocardial oedema. Thereafter, a gadolinium-based contrast agent was injected intravenously (Gd-GTPA, Magnevist V R , Berlex Laboratories Inc., Wayne, NJ, USA) at a dose of 0.1 mmol/kg. The early gadolinium enhancement sequence was acquired 1 min after the administration of the contrast. The LGE sequences were obtained 10 min after the administration of contrast. Details of the technical parameters for CMR sequences have been previously published. 2, 20 2.1.3 3T-CMR data analysis 2.1.3.1 Global functional and anatomical parameters. CMR data were independently analysed using dedicated software (QMass MR v.7.6, Medis, Leiden, The Netherlands) by a CMR-trained radiologist blinded to the study medication. The protocol of analysis for global functional/ anatomical parameters was performed as previously reported. 2, 21 Briefly, LV epicardial and endocardial borders were traced in each image of the cardiac phases representing the end diastole and end systole in order to obtain the left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and LVEF. LGE scar size was assessed by using manual planimetric segmentation on each slice. Same method was used for the assessment of myocardial oedema and areas of microvascular obstruction. The area of myocardial oedema was defined as the extent of the LV demonstrating high signal intensity on T2w-STIR images. The size of infarction (Day 3) or scar (Day 42) was quantified from the extent of myocardial enhancement in the LGE CMR sequence.
Cardiac remodelling parameters: WM and myocardial viability. LV regional analysis to each of the 16 American Heart
Association myocardial segments were performed. 22 The 16-segments
and not the 17-segments model were used for evaluation of WM abnormalities as the tip of the normal apex (Segment 17) does not move. To this end, an inferior right ventricular insertion point was identified and used as a reference point from which the LV was divided into the 16 circumferentially equal sectors. The endocardial and epicardial borders of the LV were defined in all the slices representing the end-diastolic and end-systolic phases. Thereafter, the end-systolic wall thickness (EST), the end-diastolic wall thickness (EDT), and the WM (WM = EST -EDT) were automatically calculated. In addition, we also determined the number of dysfunctional segments and myocardial viability as previously reported. 23 Accordingly, these two parameters were calculated as follows: dysfunctional segments were considered those segments with an EST <2 mm, whereas myocardial recovery was assessed as the percentage of segments with an EST at Day 3 <2 mm (dysfunctional segments) that presented an EST at day 42 > _2 mm (recovered segments). 23 These measurements and analyses were performed in: (i) the 16 segments (the entire LV; Supplementary material online, Figure S2A ); (ii) only including the jeopardized segments (mid-and apical-antero/septal segments; target segments 7, 8, 13, and 14; Supplementary material online, Figure S2B) ; and (iii) including those segments contra-lateral to the infracted region (basal-, mid-, and apical-inferior/lateral segments; target segments 4, 5, 10, 11, 15, and 16; Supplementary material online, Figure S2C ).
Scar size analysis by TTC staining
Although the investigation of scar size by triphenyltetrazolium chloride (TTC) staining late after reperfusion is not universally accepted, we performed the analysis with the intention of gathering some additional information. At Day 42 and after CMR analysis, hearts were arrested with potassium chloride, rapidly excised, sliced, and stained with TTC in order to determine the size of the scar by planimetry using the National Institute of Health software Image J.
Assessment of blood adenosine concentration
We assessed blood adenosine concentrations just prior MI-induction and prior reperfusion (at 1 h ischaemia). For this purpose, 4 mL of blood were directly collected into a tube containing stop solution to avoid adenosine degradation and generation. and high-weigh proteins were removed by using a 10 KDa filters (MerckMillipore). Chromatographic analysis was performed using an Agilent 1200 Series HPLC. Briefly, 50 mL of the filtrated blood samples were injected onto a 4.6Â 150 mm, 5 lm C18 columns (Agilent Technologies). The starting mobile phase consisted of 100% of methanol (MeOH) for 1 min followed by 46% of MeOH and 56% of 50 mM Na 2 HPO 4 buffer (pH = 4) for 30 min and finally 100% of Na 2 HPO 4 for 1 min. The full cycle was performed with a flow rate of 500 lL/min. A standard curve was generated with pure adenosine added to stop solution in buffer and processed as the blood samples. HPLC chromatograms were analysed by the Analyst Software (Sciex).
2.1.6 Assessment of myocardial AMP-activated protein kinase and Akt/PKB expression and activation and aquaporin-4 expression
Our previous findings in the acute setting of MI revealed a significant association between acute ticagrelor cardioprotective effects and activation of AMP-activated protein kinase (AMPK) and a reduction in aquaporin-4. 2 AMPK is known to regulate cardiac energy metabolism and to exert protection against oedema formation. 24, 25 In addition, previous studies in rodents have supported the capability of chronic ticagrelor treatment to induce protein kinase B (Akt/PKB) activation, a pro-survival protein kinase. 26, 27 In the present study, we sought to determine whether chronic administration of ticagrelor modulates cardiac aquaporin-4 expression, and AMPK and Akt/PKB expression and/or activation at 42 days post-MI. To this end, tissue samples obtained at sacrifice from the infarcted and non-infarcted myocardium of all animals were processed for protein and mRNA isolation. We performed western blot analysis to determine aquaporin-4, AMPK and Akt/PKB protein expression, and degree of activation (AMPK phosphorylated at Thr 172 or P-AMPK and Akt phosphorylated at Ser 473 or P-Akt). Results were normalized to b-actin (aquaporin-4).We also analysed the transcript levels of aquaporin-4 and AMPK by real time PCR-7000 Sequence Detection System of ABIPRISM (Applied Biosystems). The threshold cycle (Ct) values were determined and normalized to the housekeeping gene 18SrRNA in order to adjust to equal amounts of RNA.
Statistical analysis
Data were evaluated by the non-parametric Kruskal-Wallis test followed by the Mann-Whitney U test with Bonferroni correction. Results are reported as medians and interquartile range (IQR), and the v 2 of independence test was performed for the regional segmental analyses of dysfunctional segments, and linear regression analysis was performed to compare oedema and infarct size. Comparisons were carried out with the StatView (SAS Institute Inc.) and R Statistical Package. A two-sided P value less than 0.05 was considered statistically significant.
Results

Impact of MI on cardiac contractility through echocardiographic assessment
All animals showed a similar reduction of LVEF of around 30% at reperfusion as compared to baseline. In the control animals, LVEF was reduced 
Blood adenosine levels
Blood adenosine levels increased post-MI (i.e. prior reperfusion) in ticagrelor-administered animals by 1.29 ± 0.54 mM (P < 0.05 vs. baseline). In contrast, adenosine plasma levels in clopidogrel-treated pigs did not significantly increase vs. baseline (1.09 ± 1.05 mM; P = NS). There was a trend towards higher adenosine levels in the ticagrelor-administered animals as compared with clopidogrel-treated pigs (P = 0.09).
Effects of ticagrelor, clopidogrel, and placebo in global anatomical and functional parameters
Cardiac damage
The extent of oedema at Day 3 post-MI did not differ between placebo and clopidogrel-treated pigs (P = 0.33; Table 1 ). However, in the ticagrelor-treated pigs, oedema was reduced by 7 g (27%) LV vs. control and by 6 g (20%) LV vs. clopidogrel (P < 0.05 vs. control and clopidogreltreated pigs, respectively).
Compared to control animals, both P2Y 12 antagonists significantly and to a similar extent attenuated no-reflow ( Table 1) .
Both clopidogrel and ticagrelor significantly (P < 0.05) limited infarct size expansion as compared to controls at Day 3 ( Table 2) . Ticagrelor resulted in a stronger reduction as compared with clopidogrel (P < 0.05). A direct correlation was observed between infarct size and oedema formation (linear correlation coefficient r = 0.725; P = 0.001; Figure 1) .
As expected, the serial CMR assessment at 42 days post-MI verified the reduction on the fibrotic scar in all animals. Ticagrelor pigs, however, consistently showed a more pronounced reduction in the size of the scar as compared to both clopidogrel-treated pigs and controls (P < 0.05; Table 2 ). The attenuation in scar formation by ticagrelor was highly significant and the size was below the median in clopidogreltreated pigs. Post-mortem TTC-staining supported this observation [control: 9.5 (9.0-10.25)% LV; clopidogrel: 7.8 (7.3-8.7)% LV; and ticagrelor: 6.0 (5.5-7)% LV; P < 0.05 ticagrelor vs. control and clopidogrel].
Cardiac function
CMR functional analyses showed a higher LVEF at 3 days post-MI in ticagrelor-treated pigs that was maintained at Day 42 post-MI (P < 0.05 vs. control and clopidogrel groups; Table 3 ). No changes in LVEF were detected in control and clopidogrel-treated pigs over time. LV volumes (LVEDV and LVESV) significantly increased over time (P < 0.05 vs. Day 3 post-MI). Ticagrelor displayed a positive trend (P = 0.06) towards LVESV improvement vs. both control and clopidogrel-treated pigs ( Table 3) . 
Effects of ticagrelor, clopidogrel, and placebo on regional parameters associated with LV remodelling
Firstly, we evaluated WM abnormalities in the 16 segments (128 segments/group in total; Figure 2A ). As shown in Figure 2B , the mean overall segmental WM at Day 3 post-MI was 1.7 mm in control and 1.9 mm in clopidogrel-treated pigs, whereas it was 20% higher in ticagrelor-treated pigs (2.2 mm; P < 0.05 vs. control and P = 0.05 vs. clopidogrel-treated animals). Regarding the number of dysfunctional segments, 41% of the segments (n = 53) were found to be dysfunctional (WM <2 mm) in the ticagrelor-treated pigs 3 days post-MI as compared with 54% (n = 69) and 52% (n = 66) in control and in clopidogrel pigs, respectively ( Figure 2C) . At Day 42 post-MI, both control and clopidogrel pigs increased their WM to 2.1 mm and 2.4 mm, respectively, whereas it increased up to 3.4 mm in the ticagrelor group (P < 0.002; Figure 2B ). Overall myocardial viability was superior in the ticagrelor-treated pigs as compared with the clopidogrel and control pigs (57% vs. 41% and 46%, respectively, v 2 P = 0.06; Figure 2D ).
The target segments (i.e. jeopardized myocardium; n = 32 segments/ group, Figure 3A) were severely dysfunctional (akinetic and/or dyskinetic) in control and in clopidogrel pigs (0.75 mm and 0.9 mm, respectively), whereas they were mildly dysfunctional (hypokinetic) in the ticagrelor pigs (1.85 mm; P < _ 0.05 vs. control and clopidogrel; Figure 3B ). In line with these observations, the proportion of dysfunctional segments at Day 3 post-MI was 80% (n = 26 segments) and 72% (n = 23 segments) in the control and clopidogrel pigs, whereas it was 50% (n = 16) in the ticagrelor group (v 2 P < 0.05; Figure 3C ). All groups showed an improvement at 42 days post-MI (control: 1.4 mm; clopidogrel: 2.1 mm; ticagrelor: 2.2 mm; Figure 3B ) and the rate of functional recovery showed no statistical differences between the three groups ( Figure 3D ). Finally, we assessed the WM in the inferior-lateral myocardium (i.e. remote myocardium; n = 48 segments/group; Figure 4A ). Although mild, WM abnormalities were detected in a higher number of segments in control (dysfunctional segments n = 26; WM: 1.5 mm) and clopidogreltreated pigs (dysfunctional segments n = 22; WM: 1.6 mm) as compared to ticagrelor-treated pigs (dysfunctional segments n = 15; WM: 2.3 mm; P < 0.05 vs. control and clopidogrel; v 2 P = 0.06; Figure 4B and C).
Moreover, at 42 days post-MI, WM in the ticagrelor pigs was completely restored and even tended to be hyperkinetic (P < 0.002 vs. control and clopidogrel; Figure 4B ). Myocardial viability increased up to 93% in the ticagrelor group whether such functional improvements were not detected in the remote myocardium in control and clopidogrel pigs (v 2 P < 0.0001; Figure 4B and D). 3.5 Molecular effects of P2Y 12 inhibition on aquaporin-4 expression and AMPK and Akt/PKB activation Both P2Y 12 antagonists enhanced Akt/PKB protein levels in the entire myocardium ( Figure 5A and B) . Yet, ticagrelor-treated animals showed higher levels of activated Akt as compared to both clopidogrel and controls. Ticagrelor-treated animals showed a reduced aquaporin-4 protein expression in the infarcted myocardium with regards to clopidogrel and placebo-treated animals ( Figure 6A and B) . There was an enhanced expression of activated AMPK in the entire myocardium of ticagrelortreated pigs as compared with the control-and clopidogrel-treated groups (Figure 6A and B; P < 0.05).
No changes in aquaporin-4 or AMPK transcript levels were observed among the three different groups in the entire heart. As such, aquaporin- 3.6 Molecular effects of P2Y 12 antagonists on vascular density and fibrosis Chronic P2Y 12 inhibition had no impact on capillary density or new vessel formation in the infarcted cardiac region. No differences were observed in either lectin staining (Supplementary material online, Figure  S3A ) or angiogenic markers (Supplementary material online, Figure S3B) .
Regarding fibrosis, all groups showed a comparable fibrotic response at a protein expression level in the infarcted cardiac region (P < 0.05 vs. non-infarcted; Supplementary material online, Figure S4 ).
Discussion
We have recently demonstrated in pigs (the best-suited animal model for the assessment of cardioprotective therapies) 28, 29 and by CMR that despite both clopidogrel and ticagrelor protect against ischaemia/reperfusion (I/R) injury, ticagrelor does so to a greater extent than clopidogrel most likely as a consequence of its off-target properties. 2 In the present study, we expand this findings to the chronic setting and evidence, by the same experimental approach that administration of ticagrelor in the setting of MI and chronically thereafter, for the following 42 days improves cardiac contractility, limits scarring, and restores WM in the jeopardized myocardial segments. These beneficial effects are not seen in clopidogrel-treated pigs (Supplementary material online, Figure S5 ). Interestingly, the cardiac benefits of ticagrelor are found associated with molecular read-outs. As such, ticagrelor-treated animals have higher activated AMPK and Akt/PKB than clopidogrel-treated pigs. This association does not imply a causative effect of ticagrelor on AMPK/Akt but indicates overall cardiac healing. In the last decades, the improved management of acute MI patients has reduced morbidity and mortality in the acute phase; however, this success has paradoxically resulted in an increase in the incidence of heart failure due to adverse LV remodelling post-MI. 15 As a consequence, treatment efforts are currently focus on limiting the damage in the setting of acute ischaemic heart disease as well as on favouring LV repair post-infarction. A previous study in rats reported ticagrelor's ability to reduce scar size at 4 weeks post-MI. 8 Herein, we provide the first evidence that ticagrelor attenuates the deleterious effects of MI and favours the repair process in a clinically relevant pig model of MI. We demonstrate that the previously reported anti-oedema effects afforded by ticagrelor acutely 24 h post-MI 2 remain, and are even more evident at 3 days post-MI. Indeed, whereas ticagrelor diminished myocardial oedema formation by 24.5% at 24 h, 2 it was further reduced by 32% at 72 h supporting the anti-oedema effects of ticagrelor. We also show that, despite both clopidogrel and ticagrelor lowered the percentage of necrotic tissue at 3 days post-MI, the effect mediated by ticagrelor was significantly greater to that of clopidogrel, effects that correlated with the amount of oedema. Although the pathophysiological mechanisms that drive oedema formation remain to be elucidated, an oedematous reaction is known to burst upon ischaemia/reperfusion and persists for at least 1 week post-MI thereby contributing to cell injury. 30 Hence, the ability of ticagrelor to diminish oedema formation may have contributed to limit myocyte cell death, an essential feature for successful myocardial healing in the remodelling process. We must consider, however, that assessment of intracellular and/or extracellular myocardial water content would have allowed us to better determine the impact of ticagrelor over the detrimental effects of oedema on cardiac structural and functional parameters. Nevertheless, we have previously demonstrated that ticagrelor anti-oedema effects are associated with the activation of AMPK and a reduction in aquaporin-4 expression. 2 AMPK plays a critical role as a sensor to maintain cardiac energy metabolism. Yet, it also displays a pleiotropy of other cardioprotective actions including the ability to limit infarct size in the setting of ischaemia/reperfusion 31, 32 and stimulate wound healing, thereby preventing structural and functional alterations post-MI. 32, 33 Importantly, this kinase is activated by increase in adenosine nucleotide levels. In the present study, we evidence that animals chronically treated with ticagrelor show a persistent activation of AMPK above the levels observed in clopidogrel-or control-animals likely in response to increased adenosine availability. Chronic treatment with ticagrelor also reduces aquaporin-4 expression beyond the acute oedematous phase indicating a continuous preventive effect of ticagrelor on cardiac permeability and excess fluid reabsorption. 34 We also demonstrate in pigs the ability of ticagrelor to induce endogenous cardioprotection via Akt/PKB activation. 7, 8 As such, despite both P2Y 12 antagonists enhance myocardial Akt expression only ticagrelor-treated animals show a significant increase in Akt/PKB activation. Whether it is a downstream effect related to the activation of the adenosine-receptor or AMPK signalling remains to be determined. 35 Nevertheless, all together our molecular data indicate that chronic administration of ticagrelor provides a sustained activation of protective cardiac signalling pathways that extends well-beyond the ischaemia/reperfusion period and may have contributed to restore the damaged heart. In this regard, we also report that scarring remains significantly smaller in ticagrelor-treated animals as compared to clopidogrel-treated and control pigs at 42 days post-MI. 
